![Simon Jules Nebel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Simon Jules Nebel
Président chez
MARINOMED BIOTECH AG
Profil
Over the past 20 years, Simon was involved in 4 Private Equity vehicles in healthcare and renewable energy as Managing Partner at Aravis with combined assets in excess of USD 300M.
These funds invested in over 25 companies of which 19 healthcare companies; 15 healthcare companies either became public companies (SWX, ATX & NASDQ) or were acquired.
In 2016 Simon founded Viopas Venture Consulting where he is Managing Partner.
Simon has extensive experience as Board of Directors from public & private companies.
He currently holds four Board positions.
Simon holds a master and a PhD in structural biology from the Biozentrum, University of Basel as well as an MBA from the London Business School.
Postes actifs de Simon Jules Nebel
| Sociétés | Poste | Début |
|---|---|---|
| MARINOMED BIOTECH AG | Président | 02/06/2017 |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Private Equity Investor | 01/01/2002 |
Quadia SA
 Quadia SA Investment ManagersFinance Quadia invests in companies located in Europe, South America, Asia and Africa. The firm targets companies operating in the fields of clean energy, sustainable food value chain and circular products & materials. They provide financing in the form of equity and debt for growth capital requirements. | Directeur/Membre du Conseil | 01/03/2023 |
DyCare
 DyCare Medical SpecialtiesHealth Technology Develops devices that integrate wearable sensor technology to be used in medical and rehabilitation field | Directeur/Membre du Conseil | 01/02/2022 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements. | Fondateur | 01/09/2016 |
Anciens postes connus de Simon Jules Nebel
| Sociétés | Poste | Fin |
|---|---|---|
Bird Rock Bio Sub, Inc.
 Bird Rock Bio Sub, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Directeur/Membre du Conseil | 30/08/2023 |
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology Develops antibody-drug conjugates | Directeur/Membre du Conseil | 30/06/2023 |
Digital Dr. House AG | Directeur/Membre du Conseil | 31/03/2023 |
Viopas Partners AG
 Viopas Partners AG Investment ManagersFinance Zoeyplus invests in listed and private companies located across the DACH region. The firm target sectors includes biotech, medtech, healthcare and digital health companies. It provides financing for buyout transactions. | Fondateur | 31/12/2020 |
| ░░░░░░ ░░░░░░░ ░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Simon Jules Nebel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
71
Relations au 1er degré
19
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 19 |
|---|---|
Borean Pharma ApS
 Borean Pharma ApS Pharmaceuticals: MajorHealth Technology Provides biopharmaceuticals drugs and protein engineering services | Health Technology |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aravis AG
Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Finance |
London Business School
 London Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology Develops and discovers novel targeted small molecule drugs | Health Technology |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotech company focused on the research, development and commercialization of ingredients based on nature | Commercial Services |
Bird Rock Bio Sub, Inc.
Bird Rock Bio Sub, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Aravis Venture II LP
 Aravis Venture II LP Investment ManagersFinance Acts as Venture Capital Fund | Finance |
ImVisioN Therapeutics AG
 ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Operates as a holding company with interest in providing immunotherapy | Commercial Services |
Marinomed Biotech AG
 Marinomed Biotech AG Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products to treat viral and auto-immune diseases | Health Technology |
leading swiss renewables AG
 leading swiss renewables AG Financial ConglomeratesFinance Invests in and manages renewable energy development projects | Finance |
SynAffix BV
SynAffix BV BiotechnologyHealth Technology Develops antibody-drug conjugates | Health Technology |
Northern Data AG
 Northern Data AG Data Processing ServicesTechnology Services Provides hosting and bitcoin mining services | Technology Services |
Quadia SA
Quadia SA Investment ManagersFinance Quadia invests in companies located in Europe, South America, Asia and Africa. The firm targets companies operating in the fields of clean energy, sustainable food value chain and circular products & materials. They provide financing in the form of equity and debt for growth capital requirements. | Finance |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements. | Finance |
Viopas Partners AG
Viopas Partners AG Investment ManagersFinance Zoeyplus invests in listed and private companies located across the DACH region. The firm target sectors includes biotech, medtech, healthcare and digital health companies. It provides financing for buyout transactions. | Finance |
DyCare
DyCare Medical SpecialtiesHealth Technology Develops devices that integrate wearable sensor technology to be used in medical and rehabilitation field | Health Technology |
Digital Dr. House AG | |
MerLion Pharmaceuticals SA |
